Sarat Chandarlapaty Selected Research

Selective Estrogen Receptor Modulators (SERM)

9/2022	Accelerating drug development in breast cancer: New frontiers for ER inhibition.
11/2018	The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sarat Chandarlapaty Research Topics

Disease

77	Breast Neoplasms (Breast Cancer) 05/2024 - 08/2008
70	Neoplasms (Cancer) 05/2024 - 01/2008
10	Neoplasm Metastasis (Metastasis) 10/2022 - 07/2014
8	Disease Progression 05/2024 - 08/2011
6	Prostatic Neoplasms (Prostate Cancer) 01/2023 - 05/2011
4	Brain Neoplasms (Brain Tumor) 10/2022 - 07/2014
3	Carcinogenesis 10/2023 - 01/2022
3	Heart Failure 10/2022 - 07/2014
2	Lobular Carcinoma 11/2023 - 01/2021
2	Ductal Carcinoma 01/2021 - 01/2018
2	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2021 - 05/2014
2	Diarrhea 01/2021 - 01/2020
2	Hyperglycemia 01/2021 - 01/2020
1	Retinoblastoma (Glioblastoma, Retinal) 11/2023
1	Neurofibrosarcoma (MPNST) 01/2022
1	Sarcoma (Soft Tissue Sarcoma) 01/2022
1	Hypokalemia 01/2021
1	Mucositis 01/2021
1	Exanthema (Rash) 01/2020

Drug/Important Bio-Agent (IBA)

32	Estrogen ReceptorsIBA 05/2024 - 12/2013
16	Hormones (Hormone)IBA 05/2024 - 12/2013
15	Phosphotransferases (Kinase)IBA 04/2024 - 01/2008
14	Trastuzumab (Herceptin)FDA Link 03/2022 - 08/2008
13	ErbB Receptors (EGF Receptor)IBA 10/2022 - 01/2008
11	human ERBB2 proteinIBA 05/2023 - 05/2010
9	LigandsIBA 05/2024 - 11/2012
9	Fulvestrant (Faslodex)FDA Link 11/2023 - 04/2015
8	Estrogens (Estrogen)FDA Link 10/2021 - 12/2013
7	Biomarkers (Surrogate Marker)IBA 05/2024 - 03/2014
7	Cell-Free Nucleic AcidsIBA 01/2022 - 10/2016
6	DNA (Deoxyribonucleic Acid)IBA 08/2022 - 07/2017
5	Estrogen Receptor Modulators (Antiestrogen)IBA 05/2024 - 08/2017
5	capivasertibIBA 04/2024 - 07/2017
5	AlpelisibIBA 04/2024 - 04/2015
5	Androgen Receptors (Androgen Receptor)IBA 01/2023 - 05/2011
5	Progesterone Receptors (Progesterone Receptor)IBA 10/2022 - 07/2014
4	Estrogen Receptor alphaIBA 05/2024 - 02/2016
4	Immunoconjugates (Immunoconjugate)IBA 05/2023 - 01/2021
4	Protein Isoforms (Isoforms)IBA 08/2022 - 01/2015
3	Proteins (Proteins, Gene)FDA Link 05/2024 - 01/2008
3	Cadherins (E-Cadherin)IBA 11/2023 - 01/2018
3	Oncogene Proteins (Oncogene Protein)IBA 01/2023 - 06/2014
3	Aromatase InhibitorsIBA 09/2022 - 08/2017
3	pertuzumabIBA 03/2022 - 08/2017
3	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2022 - 05/2014
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 01/2008
3	Lapatinib (GW572016)FDA Link 10/2018 - 05/2010
3	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2016 - 01/2008
3	tanespimycin (17AAG)IBA 08/2011 - 01/2008
2	EnzymesIBA 05/2024 - 01/2021
2	Everolimus FDA Link 04/2024 - 03/2017
2	Cyclin-Dependent Kinase 4IBA 11/2023 - 12/2018
2	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2023 - 01/2019
2	ChromatinIBA 01/2023 - 01/2019
2	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 01/2023 - 01/2018
2	Selective Estrogen Receptor Modulators (SERM)IBA 09/2022 - 11/2018
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2022 - 10/2019
2	MethyltransferasesIBA 01/2022 - 01/2018
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2021 - 03/2014
2	Circulating Tumor DNAIBA 01/2020 - 11/2015
2	neratinibIBA 01/2020 - 10/2018
2	Cyclin EIBA 10/2019 - 03/2011
2	Tamoxifen FDA LinkGeneric 01/2019 - 11/2018
2	AndrogensIBA 01/2018 - 01/2016
2	STA 9090IBA 08/2017 - 06/2014
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2016 - 06/2014
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 03/2014 - 04/2012
2	Tyrosine Kinase InhibitorsIBA 05/2010 - 01/2008
1	Cyclin DIBA 05/2024
1	Cyclin D1IBA 05/2024
1	APOBEC-1 DeaminaseIBA 05/2024
1	Peptides (Polypeptides)IBA 05/2024
1	Retinoblastoma ProteinIBA 11/2023
1	AntigensIBA 05/2023
1	sacituzumab govitecanIBA 05/2023
1	trastuzumab deruxtecanIBA 05/2023
1	Cytotoxins (Cytolysins)IBA 05/2023
1	Steroid Receptors (Steroid Receptor)IBA 01/2023
1	Transcription Factors (Transcription Factor)IBA 01/2022
1	Verteporfin (Visudyne)FDA Link 01/2022
1	Polycomb Repressive Complex 2IBA 01/2022
1	Retroelements (Retrotransposon)IBA 01/2022
1	SteroidsIBA 10/2021
1	Androstenedione (4 Androstene 3,17 dione)IBA 10/2021
1	PTEN Phosphohydrolase (PTEN Phosphatase)IBA 04/2021
1	16-fluoroestradiolIBA 01/2021
1	RNA Splice SitesIBA 01/2021
1	CateninsIBA 01/2021
1	elgemtumabIBA 01/2021
1	PyrimidinesIBA 01/2021
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2021
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021
1	Lipase (Acid Lipase)FDA Link 01/2021
1	monomethyl auristatin EIBA 11/2020
1	ZirconiumIBA 01/2020
1	Complement System Proteins (Complement)IBA 01/2020

Therapy/Procedure

59	Therapeutics 05/2024 - 08/2008
5	Drug Therapy (Chemotherapy) 01/2018 - 01/2008
2	Neoadjuvant Therapy 03/2022 - 10/2015
1	Immunotherapy 05/2023